U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. News & Events for Human Drugs
  4. Webinar: The FDA Study Data Technical Conformance Guide v4.4 - Nov 22, 2019 - 11/22/2019
  1. News & Events for Human Drugs

Webcast | Virtual

Event Title
Webinar: The FDA Study Data Technical Conformance Guide v4.4 - Nov 22, 2019
November 22, 2019


Date:
November 22, 2019
Time:
1:00 p.m. - 2:30 p.m. ET

Follow us on LinkedIn

View Slides

This on-demand webinar is FREE. This webinar was recorded on November 22, 2019.

ABOUT THIS WEBINAR

FDA experts provide an overview of recent updates made to FDA’s Study Data Technical Conformance Guide v4.4 – recorded on Friday, November 22, 2019.

The Study Data TGC provides specifications, recommendations, and general considerations on how to submit standardized study data using FDA-supported data standards located in the FDA Data Standards Catalog. The TCG supplements the guidance for industry Providing Regulatory Submissions in Electronic Format — Standardized Study Data and provides technical recommendations to sponsors for the submission of animal and human study data and related information in a standardized electronic format in INDs, NDAs, ANDAs, and BLAs.

TOPICS COVERED

  • Updates since March 2019 sdTCG
  • Using the simplified TS.xpt
  • Section 8.2.2 specifics
    • There will be detailed examples of the intricacies of using the simplified TS.xpt with nonclinical submissions.

Intended Audience

  • Anyone involved in the collection, preparation or submission of study data to FDA.

FDA SPEAKERS

Helena Sviglin
Study Data Technical Conformance Guide, Chair
Office of Strategic Programs (OSP) | CDER | FDA

Heather Crandall
Electronic Submissions Team
Office of Business Informatics (OBI) | CDER | FDA

Stephanie Leuenroth-Quinn
Nonclinical Representative for Data Standards Development
Office of New Drugs (OND) | CDER | FDA

FDA RESOURCES


Event Materials

Back to Top